Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors

Cancer Research

Volumn 71, Issue 13, 2011, Pages 4527-4538

  Perentes, Jean Y ^a,c   Kirkpatrick, Nathaniel D ^a   Nagano, Satoshi ^a   Smith, Eve Y ^a   Shaver, Christine M ^a   Sgroi, Dennis ^b   Garkavtsev, Igor ^a   Munn, Lance L ^a   Jain, Rakesh K ^a   Boucher, Yves ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE 14;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; TUMOR GROWTH; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 14; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79959904515     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4376     Document Type: Article

References (45)

1. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70:5649-69.
2. Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?Cell Cycle 2006;5:812-7.
3. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
5. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34. (Pubitemid 43723979)
6. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
7. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92. (Pubitemid 34270240)
8. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010;1803:39-54.
9. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alpha V beta 3 integrin. Cancer Cell 2003;3:589-601. (Pubitemid 36808653)
10. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 2004;64:1687-94. (Pubitemid 38428690)
11. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004;167:769-81. (Pubitemid 39565156)
12. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006;20:2673-86. (Pubitemid 44498378)
13. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007;9:893-904. (Pubitemid 47190444)
14. Ota I, Li XY, Hu Y, Weiss SJ. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A 2009;106:20318-23.
15. Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, et al. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 2005;65:10959-69. (Pubitemid 41713365)
16. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. Faseb J 2002;16:555-64. (Pubitemid 34273239)
17. Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52.
18. Bartolome RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, et al. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol 2009;174:602-12.
19. Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, et al. Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 2007;67:4311-9. (Pubitemid 46815079)
20. Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, Okada Y, Shinagawa A, et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996;56:5678-83. (Pubitemid 26422172)
21. Cao J, Chiarelli C, Kozarekar P, Adler HL. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb Haemost 2005;93:770-8. (Pubitemid 40485416)
22. Rozanov DV, Savinov AY, Golubkov VS, Tomlinson S, Strongin AY. Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res 2006;66:6258-63.
23. Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 2008;27:3274-81. (Pubitemid 351733384)
24. Demou ZN, Awad M, McKee T, Perentes JY, Wang X, Munn LL, et al. Lack of telopeptides in fibrillar collagen I promotes the invasion of a metastatic breast tumor cell line. Cancer Res 2005;65:5674-82. (Pubitemid 40911169)
25. Porto IM, Rocha LB, Rossi MA, Gerlach RF. In situ zymography and immunolabeling in fixed and decalcified craniofacial tissues. J Histochem Cytochem 2009;57:615-22.
26. Berger R. More powerful tests from confidence interval p values. Am Stat 1996;50:314-8.
27. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26. (Pubitemid 15055349)
28. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007;104:13-9. (Pubitemid 46976633)
29. D'Alessio S, Ferrari G, Cinnante K, Scheerer W, Galloway AC, Roses DF, et al. Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem 2008;283:87-99.
30. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517-26.
31. Rowe RG, Weiss SJ. Breaching the basement membrane: who, when and how? Trends Cell Biol 2008;18:560-74.
32. Udayakumar TS, Chen ML, Bair EL, Von Bredow DC, Cress AE, Nagle RB, et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003;63:2292-9. (Pubitemid 36538639)
33. Bair EL, Chen ML, McDaniel K, Sekiguchi K, Cress AE, Nagle RB, et al. Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia 2005;7:380-9. (Pubitemid 40664227)
34. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 2003;278:40764-70. (Pubitemid 37280893)
35. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904. (Pubitemid 34289231)
36. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, Seiki M. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem 2006;281:37576-85. (Pubitemid 46042061)
37. Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 2008;283:6232-40.
38. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006;8:R28.
39. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008;19:1566-72.
40. de Mascarel I, Bonichon F, Durand M, Mauriac L, MacGrogan G, Soubeyran I, et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 1998;34:58-65. (Pubitemid 28123381)
41. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007;18:1632-40. (Pubitemid 47506249)
42. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006;94:1643-9. (Pubitemid 43924927)
43. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
44. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32. (Pubitemid 46120191)
45. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, et al. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res 2008;68:3204-13.